Repeated intravitreal ranibizumab for reactivated retinopathy of prematurity after intravitreal ranibizumab monotherapy: vascular development analysis

Xia, Fengjie; Lyu, Jiao; Peng, Jie; Zhao, Peiquan

doi:10.1007/s00417-022-05628-3

Cited by 4 publications

(14 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only 10 (8.5%) eyes experienced reactivation in the PAR subgroup, and they recovered after reinjection or LP treatment. Previous studies showed a higher recurrence rate following intravitreal IVR (4,5,12,16). Moreover, zone I ROP and APROP had a higher risk of reactivation after initial IVR, whereas complete peripheral retinal vascularization was more likely in zone II ROP (12).…”

Section: Discussionmentioning

confidence: 93%

“…Previous studies showed a higher recurrence rate following intravitreal IVR (4,5,12,16). Moreover, zone I ROP and APROP had a higher risk of reactivation after initial IVR, whereas complete peripheral retinal vascularization was more likely in zone II ROP (12). This difference may be attributed to the fact that the infants in our study were accepted for early screening based on the Chinese screening criteria.…”

Section: Discussionmentioning

confidence: 93%

“…Based on the above perspectives, the time and distance of complete vascularization may not be the rule. It was found that the rate of retinal vascularization after initial IVR was about 0.16 DD/week in infants with completed vascularization (12).…”

Section: Discussionmentioning

confidence: 99%

“…ROP eyes with lesion regression and retinal vessels that continued to grow post-IVR were included in the positive response group, and ROP eyes that deteriorated after IVR or had no change in retinal lesions were included in the negative response group. 5 Completed vascularization was de ned as retinal vessel extending to the ora serrata nasally and less than two DD temporally from the ora serrata (12,15). Eyes with ROP that did not meet the criteria stated above were included in the PAR group.…”

Section: Classi Cation Of Patientsmentioning

confidence: 99%

“…The management and potential predictors of PAR remain undetermined. Moreover, complete retinal vascularization is an ideal outcome for IVR (12). Current evidence suggests that reactivation after anti-VEGF treatment most often occurs within 60 weeks' postmenstrual age (PMA) (13).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Retinopathy of prematurity risk predictors in peripheral avascular areas after intravitreal ranibizumab treatment: Vascular outgrowth speed analysis

Chen¹,

Xiong²,

Ruan³

et al. 2022

Preprint

View full text Add to dashboard Cite

Objective To explore the predictors of risk for peripheral avascular areas (PAR) in retinopathy of prematurity (ROP) after intravitreal ranibizumab (IVR) monotherapy Methods This retrospective study included 64 infants (118 eyes) who developed type 1 ROP and received IVR between July 2019 and March 2021. Retinal vascular outgrowth speed (RVOS) was assessed by measuring the disc diameter (DD) 2 months post-IVR. Potential risk factors were examined and recorded. Logistic regression analysis and receiver operating characteristic (ROC) curves were used to determine risk factors and predict PAR values. Results Mean RVOS was 0.9 ± 0.6 DD/month in all eyes 2 months post-IVR; RVOS in treated eyes was higher than in non-treated eyes. Completed retinal vascularization was detected in 69 (58.5%) eyes, persistent PAR in 49 eyes (41.5%). Univariate logistic regression analysis showed that gestational age at birth, postnatal age (PNA) at surgery, cumulative clock hours (CCH) of the ROP lesion, RVOS after IVR, and ROP severity were individually associated with PAR. Multiple logistic regression analysis revealed that RVOS, CCH of the ROP lesion, and PNA at the time of surgery were independent risk factors for PAR. The ROC curve showed that the cutoff value for RVOS was 0.672 DD/month (area under the curve, 0.8184). Conclusions IVR treatment accelerates RVOS; RVOS is inversely related to PAR. RVOS < 0.672 DD/month was a potential predictor of PAR. CCH of the ROP lesion and PNA during surgery were independent risk factors for PAR.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Section: Classi Cation Of Patientsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Retinopathy of prematurity risk predictors in peripheral avascular areas after intravitreal ranibizumab treatment: Vascular outgrowth speed analysis

Chen¹,

Xiong²,

Ruan³

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

Retinopathy of prematurity risk predictors in peripheral avascular retina after intravitreal ranibizumab treatment: Vasculogenesis analysis Running Title: Predictors for Retinopathy Recurrence Post-Ranibizumab

Chen,

Xiong,

Ruan

et al. 2023

Preprint

View full text Add to dashboard Cite

The predictors of risk for peripheral avascular areas (PAR) in retinopathy of prematurity (ROP) after intravitreal ranibizumab (IVR) monotherapy is still unknown. This retrospective study included 64 infants (118 eyes) who developed type 1 ROP and received IVR between July 2019 and March 2021. Retinal vascular outgrowth speed (RVOS) was assessed by measuring the disc diameter (DD) 2 months post-IVR. Potential risk factors were identified to develop a predictive nomogram model for PAR. Decision curve analysis (DCA) was performed to determine the clinical utility of the nomogram model. Mean RVOS was 0.9±0.6 DD/month in all eyes 2 months post-IVR; RVOS in the treated eyes was higher than that in the non-treated eyes. Completed retinal vascularization was detected in 69 eyes (58.5%) and persistent PAR in 49 eyes (41.5%). Multiple logistic regression analysis showed that postnatal age (PNA) at IVR, ROP lesion’s cumulative clock hours (ROP_CCH), RVOS after IVR, and lesion severity were independent risk factors for PAR. DCA showed the nomogram model provides a fine net benefit. These data showed that IVR treatment accelerates RVOS. Further, RVOS is inversely related to PAR. The proposed nomogram model can potentially be effective in the individualized prediction of PAR after IVR.

show abstract

Vascular development analysis: a study for tertiary anti-vascular endothelial growth factor therapy after second reactivation of retinopathy of prematurity

Zhang,

Peng,

Yang

et al. 2024

Front. Med.

Self Cite

View full text Add to dashboard Cite

PurposeTo observe the vascular development results of tertiary anti-vascular endothelial growth factor (anti-VEGF) therapy following spontaneous second reactivation of retinopathy of prematurity (ROP).MethodsThis retrospective study included 22 infants (42 eyes) with Type 1 or aggressive ROP (A-ROP) who received three anti-VEGF drug treatments for ROP from January 2018 to December 2022. The vascular growth, possible associated risk factors, and the retinal vascularization (DB/DF ratio) were assessed.ResultsThe mean follow-up was 17.6 months. After the 3rd intravitreal injection, seven eyes showed complete vascularization (Group 1), while the remaining 35 eyes demonstrated persistent avascular retina (PAR) (Group 2). In Group 2, 17 eyes maintained a stable state and were classified in the regression subgroup. The other 18 eyes developed a 3rd reactivation (reactivation subgroup) and were treated with laser photocoagulation (LPC).Birth weight (BW) was significantly lower in Group 2 than in Group 1 (p < 0.001). The decision tree analysis shows that only infants weighing more than 1,250 g (17.50%) had a chance to achieve complete retinal vascularization. The possibility of PAR was higher in patients with BW <1,250 g than ≥1,250 g (70.00% vs. 12.50%). In addition, most infants with BW ≥ 1,290 g and initial ROP disease in Zone I or posterior Zone II developed PAR.ConclusionTertiary IVR can successfully treat a second ROP reactivation and improve peripheral retinal vascularization. BW is the most significant factor related to complete retinal vascularization. Our decision tree model may be helpful in predicting the prognosis of anti-VEGF drugs in the event of a second ROP reactivation.

show abstract

Repeated intravitreal ranibizumab for reactivated retinopathy of prematurity after intravitreal ranibizumab monotherapy: vascular development analysis

Cited by 4 publications

References 31 publications

Retinopathy of prematurity risk predictors in peripheral avascular areas after intravitreal ranibizumab treatment: Vascular outgrowth speed analysis

Retinopathy of prematurity risk predictors in peripheral avascular areas after intravitreal ranibizumab treatment: Vascular outgrowth speed analysis

Retinopathy of prematurity risk predictors in peripheral avascular retina after intravitreal ranibizumab treatment: Vasculogenesis analysis Running Title: Predictors for Retinopathy Recurrence Post-Ranibizumab

Vascular development analysis: a study for tertiary anti-vascular endothelial growth factor therapy after second reactivation of retinopathy of prematurity

Contact Info

Product

Resources

About